Can we treat sicker lung cancer patients the same as healthier ones?
NCT ID NCT04253964
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at whether non-small cell lung cancer patients who are less fit (performance status 2) can be treated just as effectively with a combination of chemotherapy and immunotherapy as those who are more fit (performance status 0-1). About 105 participants will receive pembrolizumab, and some will also get carboplatin and paclitaxel depending on their cancer type. The goal is to see if the less fit group has similar cancer control and side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Pembrolizumab, Carboplatin, Paclitaxel
What this could lead to
If successful, this could show that lung cancer patients with a lower performance status can still benefit from standard chemo/immunotherapy, expanding treatment access.
What could go wrong
This is a small, early-phase pilot study, so results may not be conclusive. Patients with poorer performance status may experience more side effects or less benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NONSMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Wake Forest Baptist Comprehensive Cancer Center
RECRUITINGWinston-Salem, North Carolina, 27105, United States
Contact Email: •••••@•••••
Contact